These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 35013596)
1. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Wang TY; Wang RF; Bu ZY; Targher G; Byrne CD; Sun DQ; Zheng MH Nat Rev Nephrol; 2022 Apr; 18(4):259-268. PubMed ID: 35013596 [TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975 [TBL] [Abstract][Full Text] [Related]
3. MAFLD and CKD: An Updated Narrative Review. Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010 [TBL] [Abstract][Full Text] [Related]
4. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273 [TBL] [Abstract][Full Text] [Related]
5. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843 [TBL] [Abstract][Full Text] [Related]
6. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976 [TBL] [Abstract][Full Text] [Related]
7. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD. Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141 [TBL] [Abstract][Full Text] [Related]
9. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601 [TBL] [Abstract][Full Text] [Related]
10. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744 [TBL] [Abstract][Full Text] [Related]
11. MAFLD and risk of CKD. Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070 [TBL] [Abstract][Full Text] [Related]
12. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis. Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293 [TBL] [Abstract][Full Text] [Related]
13. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study. Hu Q; Chen Y; Bao T; Huang Y Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233 [TBL] [Abstract][Full Text] [Related]
14. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. Theofilis P; Vordoni A; Kalaitzidis RG World J Gastroenterol; 2022 Oct; 28(39):5691-5706. PubMed ID: 36338895 [TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856 [TBL] [Abstract][Full Text] [Related]
17. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916 [TBL] [Abstract][Full Text] [Related]
18. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121 [TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated fatty liver disease in people living with HIV. Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241 [TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. Tang SY; Tan JS; Pang XZ; Lee GH World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]